2-[(Diphenylmethyl)Thio]Acetamide

We are 2-[(Diphenylmethyl)Thio]Acetamide CAS:68524-30-1 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:2-[(Diphenylmethyl)Thio]Acetamide
CAS.NO:68524-30-1
Synonyms:2-[(Diphenylmethyl)Thio]Acetamide
2-benzhydrylsulfanylacetamide
Diphenylmethyl Thioacetamide
 
Physical and Chemical Properties:
Density 1.2±0.1 g/cm3
Boiling Point 427.7±33.0 °C at 760 mmHg
Molecular Formula C15H15NOS
Molecular Weight 257.351
Flash Point 212.5±25.4 °C
 
Specification:
Appearance:White powder
Assay:≥98.0%
Residue on ignition:≤0.5%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Modafinil(CAS:68693-11-8).

2-[(Diphenylmethyl)Thio]Acetamide


Related News: Beta Bionics, Inc. recently announced it has received Breakthrough Device designation from the US FDA for its investigational iLet Bionic Pancreas System.2-ciclohexil-2-hidroxi-2-fenilacetato de metilo CAS:10399-13-0 Remogliflozin is economical than other similar agents currently available in sodium glucose co-transporter-2 (SGLT2) inhibitors class, which shall help for its better access among middle and low socio-economic strata of the society, he added.210169-05-4 Capacity: the bottleneck of business growth, expanding capacity and increasing utilization become a trend. Capacity is the core factor that determines the supply capacity of API companies. Insufficient capacity will cause companies to selectively complete orders and produce varieties, limiting the expansion of API products and market development.1,4-dibromobenceno CAS:106-37-6 Taking Teva as an example, it has 2 large R & D centers and 3 professional R & D centers in 5 countries, which effectively supports the development of Teva’s generic pharmaceutical sector.This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.

Related Products
Product Name
2-Methyl-4-amino-6-methoxy-s-triazine View Details
2-(5-Chloro-2-Benzotriazolyl)-6-Tert-Butyl-p-Cresol View Details
Triphenylen-2-ylboronic acid View Details
2-(TRIFLUOROMETHYL)PHENYL ISOTHIOCYANATE manufacturer Tripeptide-3 manufacturer 2-Methyltetrahydrofuran manufacturer 3-(Trifluoromethoxy)benzyl chloride manufacturer (S)-benzyl 2-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate manufacturer